ClinVar Miner

Submissions for variant NM_000548.5(TSC2):c.4232G>A (p.Ser1411Asn)

gnomAD frequency: 0.00001  dbSNP: rs1267811475
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000702874 SCV000831746 uncertain significance Tuberous sclerosis 2 2023-11-02 criteria provided, single submitter clinical testing This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 1411 of the TSC2 protein (p.Ser1411Asn). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with TSC2-related conditions. ClinVar contains an entry for this variant (Variation ID: 579558). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt TSC2 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV002332493 SCV002632811 uncertain significance Hereditary cancer-predisposing syndrome 2020-06-25 criteria provided, single submitter clinical testing The p.S1411N variant (also known as c.4232G>A), located in coding exon 33 of the TSC2 gene, results from a G to A substitution at nucleotide position 4232. The serine at codon 1411 is replaced by asparagine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Fulgent Genetics, Fulgent Genetics RCV002477621 SCV002791492 uncertain significance Lymphangiomyomatosis; Isolated focal cortical dysplasia type II; Tuberous sclerosis 2 2021-11-15 criteria provided, single submitter clinical testing
GeneDx RCV003313136 SCV004012584 uncertain significance not provided 2023-09-11 criteria provided, single submitter clinical testing Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 25925381)
Baylor Genetics RCV003465625 SCV004206848 uncertain significance Isolated focal cortical dysplasia type II 2023-09-11 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.